E N D
1. Community Pharmacy Today Whats really going on out there?
ASAP Annual Industry Conference
January 26-28, 2006
Bruce Kneeland
PharmacyConnections
2. Program Overview
Welcome & Introduction
High Level Stats
Bruces Top Ten List
Case Studies & Commentary
Conclusion and Q & A
3. Introduction
You can observe a lot just by watching.
Yogi Bera
5. R.Ph. Chain Store Openings
6. Drug Store Count
7. NCPA Independents
8. Bruces Top Ten List Technology Overload
The Front End Dilemma
Store Security & Business Interruption
Curb Appeal
Multiculturalism
9. Bruces Top Ten List Supply Chain Integrity
*Advertising, Marketing and
Merchandising
*? Molecular ? Chains
*Ownership Transition
*Training
10. 1. Advertising, Marketing & PR Data Mining
Referral Sources
Disease State Management
Third Party Opportunities
Key Rx Markers
Tools
Maps, reports, letters, signs, calendars
11. 2. Molecular Chains Case Study
John X
8 stores
2 with his wife
3 with another partner
2 with another partner
No Common Name
No Common Concept
12. 3. Ownership Transition Case Study
John Y
10 Drug Stores, 2 specialty Card and Gifts
Age 60 plus
Second Generation
No robots
17 Pharmacists
?Medicare Part D
Starting to wonder who to sell to
13. 4. Training Case Study
John Z & three grown children
8 Stores
Upstairs Training Center
Computer Room
HIPAA Disks
Formal program/tracking/feedback
14. Meet Don Grove One Store in Warsaw, MO
Compounding, DME, POS, Plasma Screen TV, Head phones, key fobs
Rx Building Process
15. Major Pharmacy Partners
Wholesaler
Computer Vendor
Retail Buying Group
16. Full Service WholesalersA Bakers Dozen2004 - ($mil) McKesson - $70,471
Cardinal - $57,948
AmerisourceBergen - $51,604
Kinray $3,050
Morris & Dickson $ no est.
The F. Dohmen Co. $2,080
HD Smith $1,817
Smith Drug - $1,118
N.C. Mutual - $698
Value Drug - $629
RDC Rochester - $458
McQueary Bro. - $ no est.
Valley Wholesale - $105
17. Retail Buying Groups About 30 or more
Range 3500 to 50 stores
FPN Federation of Pharmacy Networks 22 members
Wholesalers Generics Third Party
Legislative/Regulatory Issues
Business Model Changes Looming
18. Conclusion Community Pharmacy
Big & Little Chains, Molecular Chains & Independents
Effective and Efficient
Think beyond operations
Align, Coordinate, Collaborate
19. The End
Thank You